Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70

PLoS Genetics

Volumn 6, Issue 1, 2010, Pages

  Singh, Laishram R ^a   Gupta, Sapna ^a   Honig, Nicholaas H ^a   Kraus, Jan P ^b   Kruger, Warren D ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Children's Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALCOHOL; CYSTATHIONINE BETA SYNTHASE; HEAT SHOCK PROTEIN 26; HEAT SHOCK PROTEIN 70; PROTEASOME INHIBITOR; PROTEIN P53; BORONIC ACID DERIVATIVE; BORTEZOMIB; ENZYME INHIBITOR; PROTEASOME; PYRAZINE DERIVATIVE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; GENE; GENE DELETION; GENE EXPRESSION; HOMOCYSTINURIA; HUMAN; HUMAN CELL; IN VIVO STUDY; MISSENSE MUTATION; MOUSE; MUTANT; NONHUMAN; PROTEIN FUNCTION; SACCHAROMYCES CEREVISIAE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; MUTATION;

SACCHAROMYCES CEREVISIAE;

ANIMALS; BORONIC ACIDS; CELL LINE; CELLS, CULTURED; CYSTATHIONINE BETA-SYNTHASE; ENZYME ACTIVATION; ENZYME INHIBITORS; FIBROBLASTS; GENE EXPRESSION; HOMOCYSTINURIA; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SACCHAROMYCES CEREVISIAE;

EID: 76749160942     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1000807     Document Type: Article

References (47)

1. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, et al. (2003) Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21: 577-581.
2. Bross P, Corydon TJ, Andresen BS, Jorgensen MM, Bolund L, et al. (1999) Protein misfolding and degradation in genetic diseases. Hum Mutat 14: 186-198.
3. Kruger WD, Wang L, Jhee KH, Singh RH, Elsas LJ, 2nd (2003) Cystathionine beta-synthase deficiency in Georgia (USA): correlation of clinical and biochemical phenotype with genotype. Hum Mutat 22: 434-441.
4. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, et al. (1985) The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37: 1-31.
5. Wilcken DE, Wilcken B (1997) The natural history of vascular disease in homocystinuria and the effects of treatment. Journal of Inherited Metabolic Disease 20: 295-300.
6. Yap S, Naughten ER, Wilcken B, Wilcken DE, Boers GH (2000) Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. Semin Thromb Hemost 26: 335-340.
7. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, et al. (2001) Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 21: 2080-2085.
8. Gupta S, Kühnisch J, Mustafa A, Lhotak S, Schlachterman A, et al. (2009) Mouse models of cystathionine β-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia. FASEB J 23: 883-893.
9. Varley JM (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21: 313-320.
10. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, et al. (2009) Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations. J Clin Oncol 27: 1250-1256.
11. Esrig D, Spruck CH 3rd, Nichols PW, Chaiwun B, Steven K, et al. (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Amer J Path 143: 1389-1397.
12. Cooper EVB DN, Stenson PD, Phillips AD, Howells K, Mort ME (2009) The human gene mutation database at the institute of medical genetics at Cardiff.
13. Goyette P, Frosst P, Rosenblatt DS, Rozen R (1995) Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Amer J Hum Genet 56: 1052-1059.
14. Singh LR, Kruger WD (2009) Functional rescue of mutant human cystathionine β-synthase by manipulation of Hsp26 and Hsp70 levels in Saccharomyces cerevisiae. J Biol Chem 284: 4238-4245.
15. Young JC, Agashe VR, Siegers K, Hartl FU (2004) Pathways of chaperonemediated protein folding in the cytosol. Nat Rev Mol Cell Biol 5: 781-791.
16. Hartl FU, Hayer-Hartl M (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295: 1852-1858.
17. Kraus JP, Janosik M, Kozich V, Mandell R, Shih V, et al. (1999) Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat 13: 362-375.
18. Lee DH, Goldberg AL (1998) Proteasome inhibitors cause induction of heat shock proteins and trehalose, which together confer thermotolerance in Saccharomyces cerevisiae. Mol Cell Biol 18: 30-38.
19. Kim D, Li GC (1999) Proteasome inhibitors lactacystin and MG132 inhibit the dephosphorylation of HSF1 after heat shock and suppress thermal induction of heat shock gene expression. Biochem Biophys Res Com 264: 352-358.
20. Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657.
21. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, et al. (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 92: 3963-3967.
22. Shan X, Wang L, Hoffmaster R, Kruger WD (1999) Functional characterization of human methylenetetrahydrofolate reductase in Saccharomyces cerevisiae. J Biol Chem 274: 32613-32618.
23. Wang L, Chen X, Tang B, Hua X, Klein-Szanto A, et al. (2005) Expression of mutant human cystathionine beta-synthase rescues neonatal lethality but not homocystinuria in a mouse model. Hum Mol Genet 14: 2201-2208.
24. Chen X, Wang L, Fazlieva R, Kruger WD (2006) Contrasting behaviors of mutant cystathionine beta-synthase enzymes associated with pyridoxine response. Hum Mutat 27: 474-482.
25. DePristo MA, Weinreich DM, Hartl DL (2005) Missense meanderings in sequence space: a biophysical view of protein evolution. Nat Rev Genet 6: 678-687.
26. Meier M, Janosik M, Kery V, Kraus JP, Burkhard P (2001) Structure of human cystathionine beta-synthase: a unique pyridoxal 5′-phosphate- dependent heme protein. Embo J 20: 3910-3916.
27. Mu TW, Fowler DM, Kelly JW (2008) Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol 6: e26. doi:10.1371/journal.pbio.0060026.
28. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, et al. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nature Med 10: 402-405.
29. Gilardini A, Marmiroli P, Cavaletti G (2008) Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity? Curr Med Chem 15: 3025-3035.
30. Jagannath S, Vij R, Stewart K, Somlo A, Jackubowiak A, et al. (2009) Final resutls of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma. 2009 ASCO Annual Meeting. Orlando Fl: J. Clin Oncol. pp 15S (abstr 8504).
31. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, et al. (2007) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13: 1775-1782.
32. Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, et al. (2008) Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle and Nerve 38: 837-844.
33. Soussi T, Wiman KG (2007) Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303-312.
34. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecularweight compound. Nat Med 8: 282-288.
35. Bykov VJ, Selivanova G, Wiman KG (2003) Small molecules that reactivate mutant p53. European Journal of Cancer 39: 1828-1834.
36. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, et al. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research 59: 2615-2622.
37. Kruger WD (1994) A yeast system for expression of human cystathionine betasynthase: structual and functional conservation of the human and yeast genes. Proc Natl Acad Sci USA 91: 6614-6618.
38. Kruger WD, Cox DR (1995) A yeast assay for functional detection of mutations in the human cystathionine beta-synthase gene. Hum Mol Genet 4: 1155-1161.
39. Shan X, Kruger WD (1998) Correction of disease-causing CBS mutations in yeast. Nat Genet 19: 91-93.
40. Tang B, Li YN, Kruger WD (2000) Defects in methylthioadenosine phosphorylase are associated with but not responsible for methionine-dependent tumor cell growth. Cancer Res 60: 5543-5547.
41. Tang B, Kadariya Y, Murphy ME, Kruger WD (2006) The methionine salvage pathway compound 4-methylthio-2-oxobutanate causes apoptosis independent of down-regulation of ornithine decarboxylase. Biochem Pharmacol 72: 806-815.
42. Moat SJ, Bao L, Fowler B, Bonham JR, Walter JH, et al. (2004) The molecular basis of cystathionine beta-synthase (CBS) deficiency in UK and US patients with homocystinuria. Hum Mutat 23: 206.
43. de Franchis R, Kraus E, Kozich V, Sebastio G, Kraus JP (1999) Four novel mutations in the cystathionine beta-synthase gene: effect of a second linked mutation on the severity of the homocystinuric phenotype. Hum Mutat 13: 453-457.
44. Hu FL, Gu Z, Kozich V, Kraus JP, Ramesh V, et al. (1993) Molecular basis of cystathionine beta-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. Hum Mol Genet 2: 1857-1860.
45. Shan X, Dunbrack RL Jr, Christopher SA, Kruger WD (2001) Mutations in the regulatory domain of cystathionine beta synthase can functionally suppress patient-derived mutations in cis. Hum Mol Genet 10: 635-643.
46. Wang L, Jhee KH, Hua X, DiBello PM, Jacobsen DW, et al. (2004) Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice. Circ Res 94: 1318-1324.
47. Gupta S, Wang L, Hua X, Krijt J, Kozich V, et al. (2008) Cystathionine bsynthase p.S466L mutation causes hyperhomocysteinemia in mice. Hum Mutat 29: 1048-1054.